INTRODUCTION
The lung extracellular matrix (ECM) consists of collagen and elastic fibers interspersed with structural glycoproteins and proteoglycans (PGs) (8) . Proteoglycans, a heterogeneous group of macromolecules, consist of a core protein to which glycosaminoglycan (GAG) chains are covalently attached. PGs influence lung tissue mechanical properties, and through their interactions with various macromolecules, contribute to a variety of biological functions such as water balance, cell adhesion, cell migration and growth factor binding within the ECM (1, 20, 33) . Versican (VS), the large aggregating chondroitin sulfate containing PG, forms macromolecular aggregates with hyaluronic acid in the lung interstitial matrix. In addition, perlecan, a heparan sulfate PG, and several small leucine-rich repeat PGs, i.e., biglycan, decorin, fibromodulin and lumican, have been identified in the lung tissue (11, 33, 43) . Changes in ECM synthesis and degradation play a part not only in physiological processes such as development, growth and aging but also in wound healing, inflammation and fibrosis (33, 37) .
Bleomycin (BM)-induced pulmonary fibrosis, a well established animal model for the study of human pulmonary fibrosis, is an inflammatory interstitial lung disease characterized by excessive accumulation of fibroblasts and ECM molecules, including PGs, in the intraluminal and interstitial compartments of the lung (8, 40, 43) . Evidence from human studies and animal models indicates that TGF-β1 plays a pivotal role in mediating pathophysiological changes in fibrotic diseases (37) . TGF-β1 stimulates fibroblasts to synthesize large amounts of ECM proteins. TGF-β1 levels are upregulated in patients with cryptogenic fibrosing alveolitis and also in BM-induced lung fibrosis in rats (23) .
Fibroblasts participate in inflammatory responses and wound repair through their ability to release cytokines, secrete ECM proteins and through cell-cell interactions with other FINAL ACCEPTED VERSION LCMP-00061-2002.R1
3 inflammatory cells such as macrophages. At sites of injury and wound repair, fibroblasts have been shown to migrate from different anatomic sites and transform into a less proliferative but more contractile and collagen synthetic phenotype (14, 32) . It has been reported that lung fibroblasts cultured from BM-induced fibrotic rat lungs produced more collagen than NLF in culture (30) . Furthermore, Raghu et al. , demonstrated that TGF-β1 stimulated collagen production and collagen mRNA levels in fibroblasts derived from normal and fibrotic human lungs (31) .
Whereas the effect of TGF-β1 on collagen expression in NLF and BLF has been relatively well defined, the pattern of synthesis of PGs by NLF and BLF and the effects of TGF-β1 on PG production have not been investigated. This is of particular interest because PGs are one of the first ECM components to be upregulated in the fibrotic process and may be critical in establishing the provisional matrix necessary for subsequent cell migration and proliferation (33) . Moreover, an increase in TGF-β1, both at the messenger and protein levels, occurs well before any detectable increase in the expression of collagens in BM-induced pulmonary fibrosis (19) . We have recently reported marked increases in both the large and small PGs in BMinduced pulmonary fibrosis in intact rats (12, 40) . Based on these observations, we hypothesized that the upregulation of PGs in fibrotic lungs may be due to an increase in the biosynthetic activity of resident fibroblasts. Moreover, we postulated a role for TGF-β1 in this process, as has been shown in other organ systems (4, 22 fibroblast proliferation, and the production of collagenous and non-collagenous ECM proteins (9) . Gurujeyalakshmi and Giri (17) reported that IFN-γ downregulates TGF-β1 and collagen gene expression in the bleomycin-model of lung fibrosis. IFN-γ has also been shown to inhibit the growth of fibroblast cultures and collagen synthesis derived from normal and fibrotic human lungs (27) . However, the role of IFN-γ in providing protection against increases in PG production by bleomycin lung fibroblasts remains poorly defined.
Therefore, we compared PG production by NLF and BLF. We also investigated the modulating effect of TGF-β1 on PG production, and determined whether endogenous TGF-β-induced increases in PG production would be abrogated by the addition of neutralizing anti-TGF-β antibodies. Finally, the anti-fibrotic effect of IFN-γ on TGF-β1-induced increases in proteoglycan expression was studied.
MATERIALS AND METHODS

Chemicals
Reagents were obtained from the following sources: bleomycin (Blenoxane) from Bristol-Myers FBS, containing 2 mM L-glutamine, 0.37 g of sodium bicarbonate/100 ml, 200 Units of penicillin/ml, 200 µg/ml of streptomycin sulfate and 2.5 µg/ml of fungizone. Cells were passaged every 3-5 days and by the fourth passage they were homogeneous monolayers (morphologically consistent with fibroblast-like cells, phase contrast light microscopy).
Experiments were carried out with fibroblasts between 4 th and 6 th passages.
Phenotypic characterization of lung fibroblasts
Immunofluorescent staining was used to characterize the phenotype of isolated lung fibroblasts. 
Determination of cell proliferation and cell viability
Characterization of PGs synthesized by fibroblasts in culture
Fibroblasts were grown to confluence, and then serum deprived (0.1% FBS) for 24 h before stimulation with TGF-β1 (5 ng/ml), anti-TGF-β antibody (1, 5, 10 µg/ml), IFN-γ (5, 50, 500 U/ml) or TGF-β1+IFN-γ (5, 50, 500 U/ml) for 48 hr. The amount of TGF-β1 used in the present study was based on a previous study on collagen production using fibroblasts derived from fibrotic human lung (31) . At the end of the experimental period, PGs were fractionated into cell layer and medium compartments. The cell layer was rinsed three times with PBS and extracted with ice cold 4 M GuHCl/50 mM sodium acetate, pH 5.8/1% Triton X-100 containing proteinase inhibitor cocktail: 100 mM 6-aminohexanoic acid/10mM EDTA/5 mM benzamidine 
Composite agarose-PAGE and Western blotting of versican and HSPG
Electrophoretic separation of large PGs was performed in a composite gel (0.6% agarose:1.2% polyacrylamide) as described previously (40 
Measurement of TGF-β1 in cell-conditioned medium
The concentration of TGF-β1 released by NLF and BLF was determined using a human TGF-β1
enzyme-linked immunosorbent assay kit (R&D Systems) that detects rat TGF-β1 protein.
Briefly, NLF and BLF were plated and grown to confluency in complete medium containing FINAL ACCEPTED VERSION LCMP-00061-2002.R1 10 10% FBS. Then these cells were washed in PBS and incubated in a serum-free medium containing 0.2 mg/ml bovine serum albumin. The medium was changed every 4 hours for a period of 24 h. After 24 h, the conditioned media were separated from cells and centrifuged. The cell-free conditioned media were assayed for TGF-β1 after acidification and neutralization according to the manufacturer's protocol. All assays were done in duplicate wells. The assay detects only the active form of TGF-β1, and the results, normalized to equal number of cells, were expressed as ng/ml/10 6 cells.
Statistical analysis
All data are presented as the mean ± SD of three observations. Student's unpaired t-test was used to analyze the statistical significance of the differences between the results of NLF and BLF, and that of cells treated with or without TGF-β1. One-way analysis of variance (ANOVA) with post hoc Bonferroni correction was used to determine the significance of dose-response studies with neutralizing anti-TGF-β antibody and IFN-γ. Statistical analyses were performed using GraphPad Prism software (version 3.0).
RESULTS
Characterization of lung fibroblasts
Immunofluorescent studies on cultured cells revealed that both NLF (Fig. 1A) and BLF (Fig. 1B) were strongly positive for vimentin (a fibroblast marker). There was no systematic difference between NLF and BLF in the staining pattern of vimentin. We also stained the isolated fibroblasts with α-SMA (a smooth muscle marker). The results demonstrated that NLF (Fig. 1C) FINAL ACCEPTED VERSION LCMP-00061-2002.R1 11 expressed a weak signal for α-SMA, whereas BLF (Fig. 1D ) contained more cells positive for α-SMA.
Growth rate and cell viability
In a previous study, we observed a maximal increase in lung PGs at 14 days post-BM treatment (40) : lung fibroblasts were isolated at this time point in the current study. The growth rate of BLF did not differ significantly from NLF (data not shown). Since TGF-β1 is a potent regulator of growth, cell proliferation was also measured in the presence of exogenously added TGF-β1.
The results revealed no change in proliferation rate indicating TGF-β1 did not affect growth rates in either NLF or BLF. We were also interested in determining whether TGF-β1 or anti-TGF-β antibody had any cytotoxic effects on these fibroblasts. To this end, we used the trypan blue exclusion method to assess cell viability. Our results indicated that neither TGF-β1 nor anti-TGF-β antibody caused detachment of cells from the culture flask. More than 95% of cells were attached to the culture flask and excluded trypan blue stain.
BLF express increased amounts of PGs at the protein levels in vitro
Similar results were obtained for both the cell layer and medium compartments with regard to PG expression, and therefore in the present study, we present the data obtained from the cell layer.
Our data indicate that NLF and BLF differ in their ability to produce PGs in vitro. BLF demonstrated a 7.3-fold increase in the in vitro expression of VS (Fig. 2B ) in the cell layer in comparison with NLF ( Figure 2A ). Two immunoreactive bands were detected on composite gels for VS, suggesting that the protein has two isoforms perhaps due to alternative splicing of the FINAL ACCEPTED VERSION LCMP-00061-2002.R1 12 versican gene. We observed a 3.6-fold increase of HSPG in the cell layer of BLF (Fig. 3B ) as compared with NLF (Fig. 3A) . Finally, BLF (Fig. 4B ) produced larger amounts (3.5-fold increase) of cell-associated BG in comparison with NLF (Fig. 4A) .
BLF secrete higher amounts of TGF-β1 protein
To investigate the hypothesis that enhanced expression of PGs in BLF may be due to increased expression of TGF-β1, we measured the levels of TGF-β1 released in serum-free cellconditioned media of NLF and BLF. Our results demonstrated that there was a significant increase (3.4-fold increase) in TGF-β1 protein secreted by BLF (Fig 5) as compared to NLF.
TGF-β1 upregulates PG expression in NLF and BLF in vitro
After exposure to TGF-β1 (5 ng/ml) there was a 2-fold increase in VS in the cell layer of BLF (Fig. 1B) . BLF exposed to TGF-β1 exhibited a 3.8-fold increase of HSPG in the cell layer ( Fig.   3B ) and a 3.2-fold increase in the cell-associated BG (Fig. 4B) .
Similarly, NLF increased the expression of PGs at the protein level in response to TGF-β1 stimulation. A 4.4-fold increase in the expression of VS in the cell layer was observed for NLF treated with TGF-β1 ( Fig. 2A) . NLF treated with TGF-β1 demonstrated a 5.5-fold increase for cell-associated HSPG (Fig. 3A) . Similarly, a 3.6-fold increase in the expression of BG in the cell layer was noted for NLF treated with TGF-β (Fig. 4A) .
Neutralizing antibody to TGF-β decreases PG expression in fibroblasts
There was a dose-dependent decrease in PG expression in response to neutralizing antibody.
Whereas the lowest concentration (1 µg/ml) of anti-TGF-β antibody had no inhibitory effect on PG expression, incubation with 5 and 10 µg/ml significantly modulated PG production. As Figure 1B , anti-TGF-β antibody at 5 and 10 µg/ml inhibited 48.9% and 86.7% of VS expression, respectively, in the cell layer, obtained for BLF. Anti-TGF-β antibody treatment resulted in a 57.4% and 80.8% inhibition of HSPG expression in the cell layer (Fig. 3B ) at 5 and 10 µg/ml, respectively, in BLF. Anti-TGF-β antibody treatment led to a 40.9% and 62.6%
inhibition of BG in the cell layer at 5 and 10 µg/ml (Fig. 4B) , respectively, for BLF.
We also investigated whether NLF responds to the antifibrotic effects of anti-TGF-β antibody. Neutralizing antibody significantly reduced the basal levels of PG expression in NLF.
Quantification of Western blots of cell-associated PGs showed that anti-TGF-β antibody at 10 µg/ml inhibited 53.6% of VS expression in NLF ( Fig. 2A) . Similarly, NLF treated with 10 µg/ml demonstrated a significant decrease in HSPG production (54.5% inhibition for cell layer PGs; Fig. 3A) . Treatment of NLF with 10 µg/ml of anti-TGF-β antibody resulted in a 54% inhibition in the expression of cell-associated BG (Fig. 4A) . These results clearly indicate that inhibition of endogenous TGF-β activity results in downregulation of PGs in both NLF and BLF.
IFN-γ reduces PG expression in fibroblasts
To determine whether IFN-γ can suppress PG protein expression in BLF, we used three different concentrations of IFN-γ (5, 50 or 500 U/ml). We found that the two lower concentrations (5 and 50 U/ml) had no significant effect in reducing PG production, whereas IFN-γ at 500 U/ml markedly decreased PG expression. A 64%, 63% and 62% inhibition of VS (Fig. 2B) , HSPG ( Fig. 3B) and BG (Fig. 4B ) expression, respectively, was observed in the cell layer of BLF treated with 500 U/ml of IFN-γ. We were also interested to determine if IFN-γ treatment would block the TGF-β1-induced increases in PG expression by fibroblasts. Whereas the two lower FINAL ACCEPTED VERSION LCMP-00061-2002.R1 14 concentrations (5 or 50 U/ml) of IFN-γ resulted in no inhibitory effect on PG expression, IFN-γ treatment at a dose of 500 U/ml resulted in a 74%, 61%, and 76% inhibition of VS ( Fig. 2A) , HSPG (Fig. 3A) , and BG (Fig. 4A) , respectively, in NLF treated with TGF-β1. Similarly, IFN-γ treatment resulted in a 75%, 78%, and 67%, inhibition of VS (Fig. 2B) , HSPG (Fig. 3B) , and BG (Fig. 4B) , expression, respectively, in BLF treated with TGF-β1.
DISCUSSION
The most significant findings of the present study are (i) BLF produced larger amounts of all classes of PGs than NLF, (ii) BLF secreted increased amounts of TGF-β1 protein than NLF, (iii) exposure of fibroblasts to exogenous TGF-β1 stimulated these cells to produce more PGs than untreated cells (iv) anti-TGF-β antibody inhibited the levels of PGs expressed by these fibroblasts in a dose-dependent fashion, and (v) IFN-γ attenuated the TGF-β1-induced increases in PG expression. In the present study, we have analyzed PG expression at the protein level. Proteoglycan expression at the mRNA level would have provided additional information, however, the presence of mRNA does not necessarily predict protein production. A previous study on cytokine regulation of PG expression in lung fibroblasts has reported that changes in mRNA levels for the various PGs were not consistent with changes in protein production (38) .
We questioned whether bleomycin induced phenotypic changes in lung fibroblasts.
Previous studies have demonstrated the emergence of myofibroblasts as the predominant cell type involved in the increased deposition of ECM proteins and enhanced contractility of lung tissue in this disease process (13, 24, 26, 44) . Our findings are in agreement with these studies, in so far as the bleomycin fibroblasts showed positive staining for both vimentin and α-SMA and The importance of the marked upregulation of PGs by BLF, and the significant response to TGF-β1, are relevant to events in the development of pulmonary fibrosis. Increased VS expression may be of importance in providing the provisional matrix for cell migration and cell proliferation (2, 33) . This provisional matrix may be required for subsequent collagen deposition (2) . In this regard, VS is one of the early response ECM components to be upregulated during the development of BM-induced pulmonary fibrosis (2) . Given the observation that HSPG binds to growth factors, and regulates cell growth and cell-matrix interactions (21), its upregulation by BLF could influence many cellular functions pertinent to fibrosis. Since the core protein of BG has been shown to bind to collagens and fibronectin, it may modulate cell adhesion, cell migration and collagen fiber assembly during fibrogenic processes (35). Further, in a recent study from this laboratory, biglycan expression was correlated with biomechanical changes in lung tissue behavior (12) . Hence these molecules may also be important in determining the mechanical changes observed in this disease process.
During the development of pulmonary fibrosis, fibroblasts are exposed to a number of inflammatory mediators, including eicosanoids, immune complexes, serum components, inflammatory growth and differentiation factors and cytokines, many of which have the potential to influence fibroblast function (8) . In addition, resident fibroblasts participate in the inflammatory response with other inflammatory cells such as macrophages, resulting in fibroblast chemotaxis to sites of injury and excessive ECM synthesis and deposition (14) . As a In our study, PG production and secretion were significantly increased in BLF compared to NLF. Our results are consistent with the studies of Phan et al., (30) who reported that the BLF secreted increased amounts of collagen. Bleomycin has been reported to increase the synthesis of acidic glycosaminoglycans in cultured fibroblasts derived from carrageenin granuloma (29) . Our data are also in agreement with findings of increased fibroblast PG production in other types of fibrotic disorders: human granulation tissue fibroblasts have been shown to produce increased amounts of PGs compared to human gingival fibroblasts (18).
Enhanced ECM synthesis and deposition could be attributed to an increase in fibroblast proliferation and/or synthetic capacity. However, there was no significant difference in growth rates, as measured by in vitro cell proliferation, between NLF and BLF. Similar results were reported by Phan et al., (30) who also showed no change in growth rates of NLF and BLF. Our results are also supported by the studies of Wegrowski et al., (42) who reported that fibroblasts derived from patients with primary hypertrophic osteopathy synthesized more PG with no change in cell proliferation. Thus, the observed increases in PG production by BLF can be explained by either increased synthesis or decreased degradation. Our findings indicate an enhancement in PG biosynthetic activity by fibroblasts isolated from BM-exposed rat lungs compared to saline-exposed rat lungs. Fibroblasts may be "primed" by BM to increase PG production. This corroborates our previous in vivo findings of marked upregulation of these PGs in the lung tissue of BM-induced fibrosis in rats (12, 40) . Enhanced secretion of PGs by fibroblasts may represent a mechanism to explain increased ECM deposition in this model.
FINAL ACCEPTED VERSION LCMP-00061-2002.R1
17 TGF-β1 is believed to be a critical mediator involved in the fibrotic response through its ability to regulate ECM production (37) . Normally, TGF-β1 is expressed in bronchiolar epithelial cells and interstitial fibroblasts. However, following tissue injury and inflammation.
TGF-β1 is highly expressed in macrophages and mesenchymal, endothelial and mesothelial cells of the lung (23) . TGF-β1 is increased in biopsies from fibrotic lungs (23) . Elevations in TGF-β1 mRNA and protein content precede the increased expression of collagens in BM-induced pulmonary fibrosis (19) . BM has also been shown to modulate the expression of TGF-β1 in rat lung fibroblasts (6) . These observations indicate that TGF-β1 contributes to the general lung fibrotic process. We questioned whether this cytokine would affect production of PGs by fibroblasts in the bleomycin model. Indeed, in the current study, TGF-β1 increased the expression of PGs in both NLF and BLF. These observations are consistent with those demonstrated in previous in vitro studies using other tissue specific fibroblasts. Dermal fibroblasts exposed to TGF-β1 increased their PG levels: expression of VS, HSPG and BG was upregulated (22) . In general the response to TGF-β1 stimulation by both NLF and BLF was similar. Interestingly, it was reported previously that fibrotic human lung fibroblasts and normal lung fibroblasts exhibited a similar level of increase in collagen production in response to TGF-β1 treatment (31).
TGF-β1-induced PG production was not coupled to enhanced cell proliferation. The biological activity of TGF-β1 depends on cell type and culture conditions. Hence, in our experimental conditions, the proliferative effect of TGF-β1 may not have been evident. Our Fibroblasts isolated from fibrotic human gingiva have been demonstrated to produce more TGF-β1 in vitro than normal fibroblasts, which in turn can stimulate PG production (39) . We investigated the putative autocrine role of TGF-β1 in the over production of PGs in this model using neutralizing antibody to TGF-β isoforms. The present findings revealed that the elevated production of PGs by BLF was significantly inhibited by anti-TGF-β antibody in a dosedependent manner. At the highest dose of anti-TGF-β antibody, PG production by BLF was similar to the basal levels produced by NLF, that is, the enhanced PG synthesis was totally abrogated. Inhibition by neutralizing antibody to TGF-β of PG production to near normal levels has also been demonstrated in rat fibrotic glomeruli (5) . In addition, antibody to TGF-β reduced the levels of fibronectin, laminin and chondroitin sulfate proteoglycan in injured rat brain (25) .
The results of these studies suggest that increased production of TGF-β play a key role in the pathogenesis of fibrogenic diseases, including BM-induced lung fibrosis. Further, the significant In conclusion, our study has demonstrated that rat lung fibroblasts in culture are capable of synthesizing various PGs that are normally expressed in lung tissue. Following BM-induced lung injury, these fibroblasts respond with an increased expression of PG; TGF-β1 further activates these cells. Since anti-TGF-β antibody reduced the levels of PGs expressed by these fibroblasts to near normal levels, our observations indicate an autocrine role for TGF-β1.
Inhibition of endogenous TGF-β activity may therefore be of importance in controlling the excessive deposition of ECM components in pulmonary fibrosis. We have also demonstrated that IFN-γ suppresses the excessive production of PGs by fibrotic lung fibroblasts, and fibroblasts exposed to TGF-β1. This observation supports a potential therapeutic role for the IFN-γ via modulation of the abnormal deposition of PGs observed during pulmonary fibrosis.
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